Related Experiment Videos
Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children
Akihiro Tamura1, Kousaku Matsubara, Takayuki Tanaka
1Department of Pediatrics, Nishi-Kobe Medical Center, 5-7-1 Kojidai, Nishi-ku, Kobe, 651-2273, Japan. akihiro-tamura@nifmail.jp
Objectives:
To determine the efficacy of methylprednisolone pulse therapy for children with Mycoplasma pneumoniae pneumonia (MP) that is refractory to antibiotic treatment.
Methods:
Refractory patients were defined as cases showing clinical and radiological deterioration despite appropriate antibiotic therapy for 7 days or more. We identified 6 such children (male/female: 3/3) aged 3-9 years who were treated between 1998 and 2006. During the same period, 190 children with MP were admitted to our institution.
Results:
Common laboratory findings of the patients included cytopenia, elevated serum lactate dehydrogenase and ferritin levels, and elevated urine beta(2)-microglobulin levels, suggesting complication of hypercytokinemic condition. We initiated intravenous methylprednisolone at a dose of 30 mg/kg on 10.2+/-2.8 clinical days and administered it once daily for 3 consecutive days. Fever subsided 4-14 h after initiation of steroid pulse therapy in all patients. This dramatic effect was accompanied by rapid improvement of radiological abnormalities including infiltrates and pleural effusion, followed by improvement of laboratory abnormalities. There were no adverse events of steroid therapy.
Conclusions:
This is the first case-series study showing an effect of 3-day methylprednisolone pulse therapy on refractory MP in children. This therapy is apparently an efficacious and well-tolerated treatment for refractory MP.
Insights
Methylprednisolone pulse therapy effectively treated children with severe Mycoplasma pneumoniae pneumonia (MP) unresponsive to antibiotics. This steroid treatment rapidly resolved fever and improved lung imaging and lab results without adverse effects.
Area of Science:
- Pediatric Pulmonology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Mycoplasma pneumoniae pneumonia (MP) can be refractory to standard antibiotic treatment.
- Refractory MP may present with hypercytokinemic conditions and significant clinical deterioration.
Purpose of the Study:
- To evaluate the efficacy and safety of methylprednisolone pulse therapy for pediatric patients with antibiotic-refractory Mycoplasma pneumoniae pneumonia.
Main Methods:
- A case series of 6 children (aged 3-9 years) with refractory MP was analyzed.
- Intravenous methylprednisolone (30 mg/kg/day for 3 days) was administered to patients showing clinical and radiological worsening despite antibiotics.
Main Results:
- All patients experienced rapid fever resolution within 4-14 hours of initiating steroid pulse therapy.
- Significant improvement in radiological findings (infiltrates, pleural effusion) and laboratory abnormalities was observed.
- No adverse events associated with methylprednisolone therapy were reported.
Conclusions:
- Three-day methylprednisolone pulse therapy is an effective and well-tolerated treatment for children with refractory Mycoplasma pneumoniae pneumonia.
- This approach offers a promising therapeutic option for severe, antibiotic-resistant MP cases.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:14Myocarditis III: Medical Management
01:14Atypical Pneumonia
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:26Rocky Mountain Spotted Fever